BackgroundPrevention guidelines for infants at high risk of allergic disease recommend hydrolysed formula if formula is introduced before 6 months, but evidence is mixed. Adding specific oligosaccharides may improve outcomes.ObjectiveTo evaluate whether partially hydrolysed whey formula containing oligosaccharides (0.8 g/100 ml) (pHFâOS) can prevent eczema in highârisk infants [ISRCTN65195597].MethodsWe conducted a parallelâgroup, multicentre, randomized doubleâblind controlled trial of pHFâOS vs standard cow's milk formula. Infants with a family history of allergic disease were randomized (stratified by centre/maternal allergy) to active (n = 432) or control (n = 431) formula until 6 months of age if formula was introduced before 18 weeks. Primary outcome was cumulative incidence of eczema by 12 months in infants randomized at 0â4 weeks (375 pHFâOS, 383 control). Secondary outcomes were cumulative incidence of eczema by 12 or 18 months in all infants randomized, immune markers at 6 months and adverse events.ResultsEczema occurred by 12 months in 84/293 (28.7%) infants allocated to pHFâOS at 0â4 weeks of age, vs 93/324 (28.7%) control (OR 0.98 95% CI 0.68, 1.40; P = 0.90), and 107/347 (30.8%) pHFâOS vs 112/370 (30.3%) control in all infants randomized (OR 0.99 95% CI 0.71, 1.37; P = 0.94). pHFâOS did not change most immune markers including total/specific IgE; however, pHFâOS reduced cow's milkâspecific IgG1 (P < 0.0001) and increased regulatory Tâcell and plasmacytoid dendritic cell percentages. There was no group difference in adverse events.ConclusionpHFâOS does not prevent eczema in the first year in highârisk infants. The immunological changes found require confirmation in a separate cohort.